Conclusions: In our series, biological therapy, especially IFX and ADA, is effective and relatively safe in patients with PUK refractory to standard systemic treatment.
AB0339 COMORBIDITIES AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS PATIENTS
Background: It is well known, that atherosclerosis associated cardiovascular diseases in many cases determine the life expectancy in RA patients. At the same time, risk factors which promote the development of premature atherosclerosis, including comorbidities, remain uncertain. Objectives: to analyze comorbid conditions in RA patients under age of 50 years and assess their impact on the vascular wall (evaluated by ultrasound investigation of the carotid arteries). Methods: The study was conducted at the Department of Family Medicine, Shupyk NMAPE at the Kyiv Regional Clinical Hospital. The study included 126 RA patients, aged from 18 to 49 years (women -102 (81%), men -24 (19%), average age 43.82±8.8 years, who provided written consent to participate in research. As a control group 30 persons without any autoimmune diseases (women -25 (83.3%) men -5 (16.7%), average age 42.4±8.6 years) were examined. All RA patients and control group underwent comprehensive clinical, laboratory and instrumental examination to identify comorbid conditions including evaluation of atherogenesis by use of ultrasound examination of the carotid arteries with intima-media thickness (IMT) measurement and atherosclerosis plagues (AP) assessment. Results: The frequency of identified comorbid conditions and diseases in RA patients and control group are presented in Table 1 . The average number of comorbid diseases/conditions per RA patient significantly exceeded its number in controls (4.13 and 1.67 respectively, p<0.05); most fre- Background: Cardiovascular disease (CVD) is a major cause of mortality in patients with rheumatoid arthritis (RA). In the literature there are conflicting data on the use of statins in patients with RA, indicating a lack of attention to the issue of prevention of CVD in this category of patients. Objectives: The aim of the study was to improve the efficiency of the treatment of rheumatoid arthritis by including to the basic treatment rosuvastatin. Methods: The study included 43 patients with RA. A survey conducted by the protocol patients (DAS28 index, visual analog scale (VAS), morning stiffness). The study of lipid metabolism included: determining the level of total cholesterol (total cholesterol), HDL cholesterol (HDL) and low density (LDL), atherogenic index (AI), triglycerides (TG). Total cardiovascular risk assessment was performed using a table SCORE. Surveyed patients divided into groups: primary (n=20) (basic therapy and rosuvastatin, 10 mg 1 time per day) and comparison (n=23) (basic therapy that included methotrexate, non-steroidal anti-inflammatory drugs, glucocorticoids in medium therapeutic doses). Results: As a result of the treatment found that patients with a primary and group comparison, there was a positive dynamics of clinical indicators of inflammatory activity (DAS28, VAS, morning stiffness). In the study group experienced a significant decrease (p<0.05) at the same time as in the comparison group had a tendency to decrease. Noted a reduction parameters: CRP ( 1 37% main group and the comparison group 2 21%), ESR ( 1 39% and 2 26% respectively). Also noted the changes in the lipid profile. Significantly decreased in the study group performance total cholesterol ( 1 31% versus 2 15%), LDL cholesterol ( 1 19% against 2 8%) and AI ( 1 29% and 2 16% respectively). Conclusions: Inclusion in the complex therapy of patients with RA statins contributes to a significant reduction in total cholesterol, LDL cholesterol, and positively affects the activity of the process, reducing the levels of acute phase proteins. Additional indications for the purpose of statins have high activity process and late onset. The use of statins in RA, given their lipid-lowering and anti-inflammatory effects, may be an effective means for the successful prevention of cardiovascular complications. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5983
